Introduction {#sec1}
============

Carcinosarcomas (CS) are rare tumors which consist of two malignant components, namely epithelial (carcinomatous) and mesenchymal (sarcomatous). These neoplasms have been observed in various locations among which the most frequent is the uterus, where it is also known as mixed malignant Müllerian tumor (MMMT). Irrespective of the location these tumors show poor prognosis. The ambivalent morphologic presentation of CS raises questions about its origin. To date there have been proposed three main hypotheses aiming to explain the origin of this tumor: 1) the collision theory: carcinoma and sarcoma are two independent neoplasms which arise in the same location and at the same time accidentally together; 2) the combination theory: both components originate from a single stem cell which undergoes divergent differentiation; 3) the conversion theory: the mesenchymal component is derived from an epithelial one. Comparative genetic analyses performed on various CS revealed large overlaps of chromosomal aberrations in both tumor components \[[@cit0001], [@cit0002]\], which speaks in favor of the 2 and 3 hypothesis.

Epithelial-mesenchymal transition (EMT) is a process of losing the epithelial phenotype and acquiring increased migratory potential. Under physiological conditions EMT is involved in the formation of the body plan, regular differentiation of many tissues and tissue repair. Under pathological conditions EMT occurs in many carcinomas and is associated with increased aggressiveness, metastatic potential and chemoresistance. It is generally believed that occurrence of the sarcomatous component of CS is a result of complete EMT \[[@cit0003]--[@cit0006]\]. However, molecular pathways involved in the process of EMT in CS are not clearly understood and might differ in anatomical locations. For example in pulmonary CS EMT is probably initiated by an upregulation of c-Jun and a consecutive overexpression of Vimentin and Fascin \[[@cit0007]\], whereas in uterine CS the Wnt signaling pathway is deregulated and Akt/beta-catenin pathway activates Slug inhibiting E-cadherin expression \[[@cit0008]\]. Among all anatomical locations the molecular landscape and pathogenesis are best explored in uterine carcinosarcoma. It is well known that *TP53* mutations are essential for CS pathogenesis as the vast majority of CS show concordant overexpression of p53 in the carcinomatous and sarcomatous component \[[@cit0009]--[@cit0011]\]. Two recent studies have demonstrated an aberrant p53 staining pattern and defective mismatch repair protein (MMR) status in a subgroup of uterine carcinosarcomas \[[@cit0012], [@cit0013]\]. In one of them p53 aberrant IHC pattern and MMR status were mutually exclusive \[[@cit0013]\]. However, there are no data about MMR status in extrauterine CS. The aim of this study was the immunohistochemical analysis of p53 and MMR status in a cohort of extrauterine CS.

Material and methods {#sec2}
====================

Cases of CS recorded at the University Clinical Centre in Gdansk from 2007 to 2015 were retrieved from the archive. Reviews of hematoxylin-eosin stained slides of each case were newly performed by two independent, board certified pathologists (PC, WB) in order to verify the diagnoses. Eventually, 28 formalin-fixed and paraffin embedded tissue blocks were analysed in our study, including tissues from lung (*n* = 8), breast (*n* = 6), head and neck (*n* = 5), ovary (*n* = 3), urinary bladder (*n* = 3), adrenal gland (*n* = 1), skin (*n* = 1), and stomach (*n* = 1) tumors.

The process of IHC and its evaluation has been described in a previous study \[[@cit0013]\]. Briefly, tumor samples were stained with antibodies against hMLH1 (Clone ES05), PMS2 (Clone EP51), hMSH2 (Clone FE 11), hMSH6 (Clone EP49), and p53 (Clone DO-7), all ready to use (DAKO, Denmark). Staining was performed on a Dako autostainer according to the manufacturer's instructions. The slides of all specimens were microscopically evaluated by two experienced pathologists (PC, WB). In the case of MMR proteins, nuclear staining was considered positive, and lack of nuclear staining as negative (a sign of defective MMR). We considered a strong/diffuse (\> 75% of tumour cell nuclei) and a completely negative staining as p53 defect indicative of its mutation, (missense and nonsense, respectively), whereas a patchy/scattered pattern was regarded as a marker of normal p53 function. All statistical analyses were performed using the Statistica 12 (Statsoft). Concordance between sarcomatoid and carcinomatous components were evaluated with Fisher's exact test and kappa test. Other categorical variables were compared by Fisher's exact test.

Results {#sec3}
=======

Immunohistochemical staining patterns of each tumor, along with basic demographic data are shown in [Table 1](#t0001){ref-type="table"}. 28 patients, 16 males and 12 females, were included in the study. Median age at diagnosis was 66.5 (range 36 to 91, average 64.85). Immunostainings for hMLH1, PMS2, hMSH2 and hMSH6 were positive in all tumors.

###### 

Summary of p53 and MMR alterations in current cohort of various carcinosarcoma

  No.   Organ                 Age   Sex      P53 IHC   MMR IHC   Epithelial component                                   Mesenchymal component
  ----- --------------------- ----- -------- --------- --------- ------------------------------------------------------ ---------------------------------------------------------
  1     Skin                  70    Male     N         N         SCC                                                    Chondrosarcoma + osteosarcoma
  2     Ovary                 64    Female   AL        N         Serous carcinoma                                       Undifferentiated spindle cells
  3     Ovary                 67    Female   AD        N         Serous carcinoma                                       Undifferentiated spindle cells
  4     Ovary                 55    Female   AD        N         Serous carcinoma                                       Undifferentiated spindle cells
  5     Adrenal gland         72    Male     N         N         Undifferentiated carcinoma                             Undifferentiated spindle cells
  6     Urinary bladder       67    Female   N         N         Urothelial carcinoma                                   Undifferentiated spindle cells
  7     Urinary bladder       67    Female   N         N         Urothelial carcinoma                                   Spindle cells with myxoid stroma
  8     Urinary bladder       61    Male     AL        N         Urothelial carcinoma                                   Undifferentiated spindle cells
  9     Lung                  75    Male     AL        N         SCC                                                    Undifferentiated spindle cells
  10    Lung                  62    Male     N         N         Large cell neuroendocrine carcinoma                    Angiosarcoma
  11    Lung                  65    Male     AL        N         SCC + adenocarcinoma                                   Chondroid differentiation
  12    Lung                  74    Male     AD        N         SCC                                                    Fibrosarcoma
  13    Lung                  68    Male     N         N         Adenocarcinoma + large cell neuroendocrine carcinoma   Undifferentiated spindle cells + myofibroblastic
  14    Lung                  59    Male     AD        N         SCC                                                    Undifferentiated spindle cells
  15    Lung                  69    Male     N         N         SCC                                                    Undifferentiated spindle cells
  16    Lung                  71    Male     AD        N         Adenocarcinoma                                         Undifferentiated spindle cells
  17    Esophagus             55    Male     N         N         SCC                                                    Undifferentiated spindle cells
  18    Esophagus             64    Male     AL        N         Anaplastic carcinoma                                   Undifferentiated spindle cells
  19    Submandibular gland   91    Male     AD        N         SCC                                                    Pleomorphic mesenchymal cells
  20    Head and neck         66    Male     N         N         SCC                                                    Chondroid differentiation
  21    Maxila                36    Male     AD        N         SCC                                                    Undifferentiated spindle cells
  22    Breast                79    Female   AL        N         Invasive ductal carcinoma, NOS                         Undifferentiated spindle cells
  23    Breast                37    Female   AD        N         SCC                                                    Osteosarcoma
  24    Breast                69    Female   AL in C   N         Invasive ductal carcinoma, NOS                         Undifferentiated spindle cells
  25    Breast                60    Female   AD        N         Invasive ductal carcinoma, NOS                         Undifferentiated spindle cells
  26    Breast                69    Female   AD        N         Invasive ductal carcinoma, NOS                         Undifferentiated spindle cells
  27    Breast                64    Female   AD        N         Invasive ductal carcinoma, NOS                         Spindle cells with myxoid stroma + large cell component
  28    Stomach               60    Male     AD        N         Adenocarcinoma with neuroendocrine differentiation     Chondroid differentiation + leiomyosarcoma

IHC -- immunohistochemistry, AD -- abnormal diffuse, AL -- abnormal loss, N -- normal, C -- carcinoma

We detected p53 defects in 19 out of 28 samples (67,85%). In almost all cases (96,42%) there was a concordance between sarcomatoid and carcinomatous components. In the breast cancer cases the p53 defect was usually reflected by its hyperexpression, while in lung by its complete absence. The patient´s characteristics are provided in [Table 1](#t0001){ref-type="table"}.

Discussion {#sec4}
==========

So far the disturbances in the MMR expression status and/or MSI status was known only in CS of the uterus \[[@cit0012]--[@cit0019]\], with the frequency between 3% \[[@cit0018]\] up to 41% \[[@cit0017]\]. Two large recent multicentre analyses showed 4% of deficient MMR expression \[[@cit0020], [@cit0021]\].

In two studies, p53 IHC aberration \[[@cit0018]\] and *TP53* mutation \[[@cit0019]\] coexisted while in our previous study we observed MLH1 IHC loss due to *hMLH1* promotor hypermethylation being mutually exclusive with an aberrant p53 staining pattern and *TP53* mutation \[[@cit0013]\].

MMR deficiency has not been described in extrauterine CS so far and our study has failed to showed it either. In a group of Lynch Syndrome patients with sarcomas there was one CS, however, it was located inside the uterus as well \[[@cit0022]\]. Our study included tumors of various sites. It has been postulated that CS/sarcomatoid carcinoma in a specific organ is similar either to ordinary carcinoma in this location rather than to CS in another anatomical location \[[@cit0006]\].

Only in sebaceous neoplasms of the skin there is a frequent loss of MMR, especially MSH2 \[[@cit0023]\], however, the sarcomatous transformation of these tumors is unknown. MMR-deficiency is infrequent in the lung, breast (around 2%) \[[@cit0024]\], head and neck (around 7%) \[[@cit0025]\], ovarian (around 4%) \[[@cit0026]\], urinary bladder (around 2%) \[[@cit0027]\], stomach (around 6%) \[[@cit0028]\] and adrenocortical carcinoma (around 3%) \[[@cit0029]\] so the lack of MMR deficiency in our small groups of patients might reflect its frequency in carcinomas.

MMR deficiency is used as a predictive biomarker for the therapeutic efficiency of immunotherapy in solid neoplasms. Our cohort is small, but our results show that MMR probably cannot be used as a predictive marker in CS and other tests should be utilized. The frequent aberrations in the expression of p53 and the almost concordance between the epithelial and mesenchymal component are in line with previous reports \[[@cit0030]--[@cit0034]\].

Conclusions {#sec5}
===========

We have observed a high frequency of aberrant p53 IHC expression in CS and their high concordance between the carcinomatous and sarcomatous components. MMR-deficiency was not observed in our group of 28 CS of variable anatomical locations so it does not seem to plays any significant role in its pathogenesis, contrary to the uterine carcinosarcoma, at least what we can state based on our limited sample size.
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